Casdin Capital 13F holdings, Q4 2017
Holdings as of December 31, 2017 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 26 US equity positions worth $409.2m in its Q4 2017 13F filing. The largest position was SG7 at 10.1% of the reported book, followed by FOUNDATION MEDICINE INC and LOXO ONCOLOGY INC. Against the Q3 2017 filing, it opened 2 new positions, added to 13 and reduced 1 among the top 26 holdings.
What did Casdin Capital own in Q4 2017? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2017 |
|---|---|---|---|---|---|---|---|
| 1 | SG7 SAGE THERAPEUTICS INC | 10.1% | $41.2m | 250,000 | 4% | added | |
| 2 | FOUNDATION MEDICINE INC | 8.7% | $35.5m | 520,000 | 8% | added | |
| 3 | LOXO ONCOLOGY INC | 7.4% | $30.3m | 360,000 | 0% | held | |
| 4 | 2655787D BLUEPRINT MEDICINES CORP | 6.4% | $26.2m | 348,000 | 17% | added | |
| 5 | BLUEBIRD BIO INC | 6.3% | $25.8m | 145,000 | 0% | held | |
| 6 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 6.2% | $25.4m | 200,000 | 0% | held |
| 7 | MYOKARDIA INC | 5.8% | $23.6m | 560,000 | 0% | held | |
| 8 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 5.6% | $23.0m | 1,400,000 | 0% | held |
| 9 | GLOBAL BLOOD THERAPEUTICS IN | 5.0% | $20.3m | 515,000 | 36% | added | |
| 10 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 4.6% | $18.8m | 1,135,000 | 39% | added |
| 11 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.1% | $16.9m | 295,000 | 16% | added |
| 12 | FATE FATE THERAPEUTICS INC | Healthcare | 3.9% | $15.9m | 2,600,000 | 373% | added |
| 13 | SPARK THERAPEUTICS INC | 3.8% | $15.6m | 302,474 | 44% | added | |
| 14 | CDXS CODEXIS INC | Healthcare | 3.3% | $13.4m | 1,600,000 | 8% | added |
| 15 | EVH EVOLENT HEALTH INC | Healthcare | 3.2% | $13.3m | 1,077,500 | 36% | added |
| 16 | AUDENTES THERAPEUTICS INC | 3.1% | $12.5m | 400,000 | 0% | held | |
| 17 | GNMK GENMARK DIAGNOSTICS INC | 2.8% | $11.4m | 2,730,000 | 82% | added | |
| 18 | ILMN ILLUMINA INC | Healthcare | 2.3% | $9.6m | 44,000 | 0% | held |
| 19 | CLOVIS ONCOLOGY INC | 2.1% | $8.7m | 127,500 | 0% | held | |
| 20 | JOUNCE THERAPEUTICS INC | 1.5% | $6.1m | 475,000 | 19% | added | |
| 21 | EDIT EDITAS MEDICINE INC | Healthcare | 1.0% | $4.1m | 133,333 | 0% | held |
| 22 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.9% | $3.7m | 177,500 | 0% | held |
| 23 | SYROS PHARMACEUTICALS INC | 0.7% | $2.7m | 274,074 | 7% | added | |
| 24 | GILD GILEAD SCIENCES INC | Healthcare | 0.5% | $2.1m | 30,000 | – | new |
| 25 | ONC BEIGENE LTD | Healthcare | 0.4% | $1.8m | 18,000 | – | new |
| 26 | OVID OVID THERAPEUTICS INC | Healthcare | 0.4% | $1.6m | 160,000 | -23% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.